// App-Quantinova.ai

570 : ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed high-risk endometrial cancer

Researchers

Presenter

  • Brian Slomovitz

Principal Investigators

  • Alain Lortholary

  • Ignace Vergote

  • David Cibula

  • Axel Walther

  • Antonella Savarese

  • Maria Pilar Barretina Ginesta

  • Firat Ortac

  • Christos Papadimitriou

  • Lubomir Bodnar

  • Chyong-Huey Lai

  • Kosei Hasegawa

  • Xiaojun Chen

  • Emma Barber

  • Robert Coleman

  • Stephen Keefe

  • Robert Orlowski

  • Toon van Gorp

Medical Centers

  • Penn Medicine, Philadelphia, PA, United States

  • University of Pennsylvania Health System, Philadelphia, PA, United States

  • Hospital of University of Pennsylvania, Philadelphia, PA, United States

Locations

  • Italy

  • United States

  • United Kingdom

  • Greece

  • Belgium

  • Czech Republic

  • Turkey

  • France

  • Poland

  • Spain

  • Denmark

  • Japan

  • China

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

Biomarkers

  • Cluster of Differentiation 206

  • p53

  • Programmed death-ligand 1

  • DNA mismatch repair status

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Paclitaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Blinded

Phase

  • III

Study Id's

  • NCT04634877

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved